Sandoz receives US FDA approval to expand Enzeevu (aflibercept-abzv) label for multiple retinal indications

18 February 2026 - Sandoz today announced that the US FDA has approved an expanded label for Enzeevu (aflibercept-abzv), to include ...

Read more →

STADA and Bio-Thera receive European marketing authorization for Gotenfia, a biosimilar to Simponi

13 February 2026 - STADA and Bio-Thera Solutions have received a marketing authorisation from the European Commission for their Gotenfia ...

Read more →

Samsung Bioepis to launch Eylea biosimilar Opuviz in Europe

30 January 2026 - Samsung Bioepis said Friday it has reached an agreement with US based firm Regeneron and Germany’s ...

Read more →

Celltrion secures Canadian approval for Omlyclo 300 mg PFS and auto-injector formulations

29 January 2026 - Celltrion said Thursday that it has received additional approval from Health Canada for its chronic idiopathic ...

Read more →

Dong-A ST receives Health Canada approval for Stelara biosimilar Imuldosa

28 January 2026 - Dong-A ST announced on Wednesday that Health Canada has granted marketing authorisation for Imuldosa (ingredient: ustekinumab), ...

Read more →

Sandoz confirms European Commission approval of Ondibta (insulin glargine), strengthening overall biosimilars leadership and position in diabetes

14 January 2026 - Expected launch by early 2027; potential to expand access to insulin treatment option for tens of millions ...

Read more →

Henlius' fifth US filing product bevacizumab biosimilar HLX04 receives FDA BLA acceptance

13 January 2026 - Shanghai Henlius Biotech announced that the biologics license application for HLX04, the Company’s independently developed bevacizumab biosimilar ...

Read more →

Amneal announces FDA approval of denosumab biosimilars referencing Prolia and Xgeva

22 December 2025 - Company expects to commercialize six biosimilars across eight presentations by 2027. ...

Read more →

Thousands more people with advanced bowel cancer to benefit as NICE approves bevacizumab biosimilars

24 December 2025 - More than 7,000 people in England will now be able to access to a life-extending treatment for ...

Read more →

Celltrion announces US FDA approval of 300 mg strength of Omyclo (omalizumab-igec), the first and only FDA approved interchangeable biosimilar to Xolair

1 December 2025 - Celltrion today announced the US FDA has approved a new presentation of Omyclo (omalizumab-igec), the first and ...

Read more →

Pre-filled syringe presentation of Byooviz, Samsung Bioepis’ biosimilar to Lucentis (ranibizumab), gains European approval

2 December 2025 - Samsung Bioepis today announced that the EMA’s CHMP has adopted a positive opinion for Byooviz pre-filled syringe, ...

Read more →

Samsung Bioepis announces launch of denosumab biosimilars, Obodence and Xbryk in Europe

1 December 2025 - Samsung Bioepis today announced the launch of Obodence (60 mg pre-filled syringe) and Xbryk (120 mg vial), ...

Read more →

Celltrion receives Health Canada approval for Eydenzelt, a biosimilar referencing Eylea (aflibercept 2 mg)

27 November 2025 - The approval is based on the totality of evidence, including analytical, nonclinical, and clinical data from global ...

Read more →

Alvotech announces approval of AVT03, a biosimilar to Prolia and Xgeva (denosumab) in the European Economic Area

November 24, 2025 - Alvotech today announced that the European Commission has approved AVT03 as a biosimilar to Prolia and ...

Read more →

Henlius and Organon announce US FDA approval of Poherdy (pertuzumab-dpzb), the first Perjeta (pertuzumab) biosimilar in the US

17 November 2025 - Shanghai Henlius Biotech and Organon today announced that the US FDA has approved the biologics license application ...

Read more →